EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation

Pan-Yu Chen, Benjamin J Huang, Max Harris, Christopher Boone, Weijie Wang, Heidi Carias, Brian Mesiona, Daniela Mavrici, Amanda C Kohler, Gideon Bollag, Chao Zhang, Ying Zhang und 1 weitere

JCI Insight · 2023

DOI: 10.1172/jci.insight.168445 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCI Insight, 2023. Verfasst von Pan-Yu Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, UCSF, San Francisco, California, USA. Hauptthemen laut MEDLINE: Leukemia, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Leukemia and Lymphoma Society, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A T50I substitution in the K-Ras interswitch domain causes Noonan syndrome and emerged as a third-site mutation that restored the in vivo transforming activity and constitutive MAPK pathway activation by an attenuated KrasG12D,E37G oncogene in a mouse leukemia model. Biochemical and crystallographic data suggested that K-RasT50I increases MAPK signal output through a non-GTPase mechanism, potentially by promoting asymmetric Ras:Ras interactions between T50 and E162. We generated a "switchable" system in which K-Ras mutant proteins expressed at physiologic levels supplant the fms like tyrosine kinase 3 (FLT3) dependency of MOLM-13 leukemia cells lacking endogenous KRAS and used this system to interrogate single or compound G12D, T50I, D154Q, and E162L mutations. These studies support a key role for the asymmetric lateral assembly of K-Ras in a plasma membrane-distal orientation that promotes the formation of active Ras:Raf complexes in a membrane-proximal conformation. Disease-causing mutations such as T50I are a valuable starting point for illuminating normal Ras function, elucidating mechanisms of disease, and identifying potential therapeutic opportunities for Rasopathy disorders and cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LeukemiaProto-Oncogene Proteins p21(ras)AnimalsMiceDisease Models, AnimalGerm CellsGerm-Line MutationMutationras Proteins

Stichwörter der Autor:innen

LeukemiasOncogenesOncology

Substanzen

Proto-Oncogene Proteins p21(ras)ras ProteinsHras protein, mouse

Autor:innen und Institutionen

  • Department of Pediatrics, UCSF, San Francisco, California, USA.
  • Plexxikon Inc., South San Francisco, California, USA.
  • Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA.

Förderung

  • NCI NIH HHS
  • Leukemia and Lymphoma Society
  • National Institutes of Health

Zitieren

APA

Chen, P. Y., Huang, B. J., Harris, M., Boone, C., Wang, W., Carias, H., Mesiona, B., Mavrici, D., Kohler, A. C., Bollag, G., Zhang, C., Zhang, Y., & Shannon, K. (2023). Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation. JCI Insight. https://doi.org/10.1172/jci.insight.168445

Vancouver

Chen PY, Huang BJ, Harris M, Boone C, Wang W, Carias H, et al. Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation. JCI Insight. 2023. doi:10.1172/jci.insight.168445

BibTeX
@article{Chen2023,
  author = {Chen, Pan-Yu and Huang, Benjamin J and Harris, Max and Boone, Christopher and Wang, Weijie and Carias, Heidi and Mesiona, Brian and Mavrici, Daniela and Kohler, Amanda C and Bollag, Gideon and Zhang, Chao and Zhang, Ying and Shannon, Kevin},
  title = {Structural and functional analyses of a germline KRAS T50I mutation provide insights into Raf activation},
  journal = {JCI Insight},
  year = {2023},
  doi = {10.1172/jci.insight.168445}
}
Kostenlos starten →